Literature DB >> 18787669

Thyroid myopathy with rhabdomyolysis presenting as agitation: a case report.

Vithyalakshmi Selvaraj, Prasad R Padala.   

Abstract

Entities:  

Year:  2008        PMID： 18787669      PMCID： PMC2528229          DOI： 10.4088/pcc.v10n0411a

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  6 in total

1.  Rhabdomyolysis due to hypothyroidism.

Authors:  Mustafa Altay; Murat Duranay; Mevlut Ceri
Journal:  Nephrol Dial Transplant       Date:  2005-02-16       Impact factor: 5.992

2.  Rhabdomyolysis disclosing hypothyroidism.

Authors:  Monsef Rabhi; Jilali Chaari; Farida Toloune
Journal:  Eur J Intern Med       Date:  2006-05       Impact factor: 4.487

3.  [Atraumatic rhabdomyolysis].

Authors:  W U Weitbrecht; B Nuber; W Sandritter
Journal:  Med Welt       Date:  1976-06-18

4.  Hypothyroidism as a cause of rhabdomyolysis.

Authors:  Maria José Barahona; Albert Mauri; Nuria Sucunza; Roger Paredes; Ana María Wägner
Journal:  Endocr J       Date:  2002-12       Impact factor: 2.349

5.  Rhabdomyolysis in a patient with hypothyroidism.

Authors:  Gurcan Kisakol; Recep Tunc; Ahmet Kaya
Journal:  Endocr J       Date:  2003-04       Impact factor: 2.349

Review 6.  [Some neurologic and psychiatric complications in endocrine disorders: the thyroid gland].

Authors:  Zsuzsa Aszalós
Journal:  Orv Hetil       Date:  2007-02-18       Impact factor: 0.540
  6 in total
  2 in total

1.  Sustained remission of psychotic symptoms secondary to hypothyroidism (myxedema psychosis) after 6 months of treatment primarily with levothyroxine: a case report.

Authors:  Eric C Chan
Journal:  J Med Case Rep       Date:  2022-10-20

Review 2.  Myxedema Psychosis: Systematic Review and Pooled Analysis.

Authors:  Mouhand F H Mohamed; Mohammed Danjuma; Mohammed Mohammed; Samreen Mohamed; Martin Siepmann; Kristian Barlinn; Salah Suwileh; Lina Abdalla; Dabia Al-Mohanadi; Juan Carlos Silva Godínez; Abdel-Naser Elzouki; Timo Siepmann
Journal:  Neuropsychiatr Dis Treat       Date:  2021-08-18       Impact factor: 2.570
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.